These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32840951)

  • 1. Evidence-practice gaps in P2Y
    Falster MO; Schaffer AL; Wilson A; Nasis A; Jorm LR; Hay M; Leeb K; Pearson SA; Brieger D
    Intern Med J; 2022 Feb; 52(2):249-258. PubMed ID: 32840951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
    Wang TY; Kaltenbach LA; Cannon CP; Fonarow GC; Choudhry NK; Henry TD; Cohen DJ; Bhandary D; Khan ND; Anstrom KJ; Peterson ED
    JAMA; 2019 Jan; 321(1):44-55. PubMed ID: 30620370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
    Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
    Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
    Dayoub EJ; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Giri J; Groeneveld PW
    JAMA Intern Med; 2018 Jul; 178(7):943-950. PubMed ID: 29799992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary use of guideline-based higher potency P2Y12 receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study.
    Patel A; Goodman SG; Tan M; Suskin N; McKelvie R; Mathew AL; Lutchmedial S; Dehghani P; Lavoie AJ; Huynh T; Lavi S; Philipp R; Khan R; Yan AT; Radhakrishnan S; Sedlak T; Brunner N; Kim HH; Cieza T; Kassam S; Fordyce CB; Heffernan M; Jedrzkiewicz S; Madan M; Ahmed S; Barry C; Dery JP; Bagai A;
    Clin Cardiol; 2021 Jun; 44(6):839-847. PubMed ID: 33982795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y
    Franchi F; Rollini F; Faz G; Rivas JR; Rivas A; Agarwal M; Briceno M; Wali M; Nawaz A; Silva G; Shaikh Z; Maaliki N; Fahmi K; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Baber U; Mehran R; Jennings LK; Bass TA; Angiolillo DJ
    J Am Heart Assoc; 2020 Apr; 9(8):e015865. PubMed ID: 32306797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
    Bagai A; Peterson ED; Honeycutt E; Effron MB; Cohen DJ; Goodman SG; Anstrom KJ; Gupta A; Messenger JC; Wang TY
    Eur Heart J Acute Cardiovasc Care; 2015 Dec; 4(6):499-508. PubMed ID: 25515725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer P2Y
    Patlolla SH; Kandlakunta H; Kuchkuntla AR; West CP; Murad MH; Wang Z; Kochar A; Rab ST; Gersh BJ; Holmes DR; Zhao DX; Vallabhajosyula S
    Mayo Clin Proc; 2022 Jun; 97(6):1074-1085. PubMed ID: 35662424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?
    Hariri E; Lessard D; Gore J; Rade J; Goldberg R
    Cardiovasc Revasc Med; 2020 Feb; 21(2):182-188. PubMed ID: 31129036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
    Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translation of experimental cardioprotective capability of P2Y
    Hjortbak MV; Olesen KKW; Seefeldt JM; Lassen TR; Jensen RV; Perkins A; Dodd M; Clayton T; Yellon D; Hausenloy DJ; Bøtker HE;
    Basic Res Cardiol; 2021 May; 116(1):36. PubMed ID: 34037861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
    Mshelbwala FS; Hugenberg DW; Kreutz RP
    J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy: a nationwide study.
    Tajchman DH; Nabi H; Aslam M; Butt JH; Grove EL; Engstrøm T; Holmvang L; Fosbøl EL; Køber L; Sørensen R
    Eur Heart J Acute Cardiovasc Care; 2021 Oct; 10(7):774-786. PubMed ID: 34570197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary use of P2Y
    Rakowski T; Siudak Z; Dziewierz A; Plens K; Kleczyński P; Dudek D
    J Thromb Thrombolysis; 2018 Jan; 45(1):151-157. PubMed ID: 29075924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
    O'Donoghue ML; Murphy SA; Sabatine MS
    Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial.
    Welsh RC; Sidhu RS; Cairns JA; Lavi S; Kedev S; Moreno R; Cantor WJ; Stankovic G; Meeks B; Yuan F; Džavík V; Jolly SS
    Can J Cardiol; 2019 Oct; 35(10):1377-1385. PubMed ID: 31492492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.